FindTrial
Sign In

Effect of PCSK9 inhibitors on patients at high risk of ASCVD

Effect of PCSK9 inhibitors on patients at high risk of ASCVD

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061083
Enrollment
Unknown
Registered
2022-06-15
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular disease

Interventions

no:no

Sponsors

The Fourth Ward of Cardiovascular Medicine of The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. Patients at high risk of ASCVD in compliance with the 2019 ESC Guidelines for Dyslipidemia Management; 3. Informed consent.

Exclusion criteria

Exclusion criteria: 1. Aged > 75 years; 2. Patients with thyroid dysfunction (hypothyroidism or hyperthyroidism) with abnormal liver or kidney function or with malignant tumors; 3. Arrhythmias or hypertension in patients with uncontrolled severe heart failure; 4.Pregnant and lactating women; 5.Any circumstances in which a person is not legally competent or has limited legal capacity or is deemed unfit to participate in the clinical study by the investigator.

Design outcomes

Primary

MeasureTime frame
no;—

Countries

China

Contacts

Public ContactTang Junnan

The First Affiliated Hospital of Zhengzhou University

fcctang@zzu.edu.cn+86 15890696166

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026